1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Human |
Cat.No | ABC-TC4044 |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Mononuclear Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Peripheral Blood |
Disease | Psoriasis |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
Human Psoriasis Peripheral Blood Mononuclear Cells are isolated from the peripheral blood of patients with psoriasis, an immune-mediated chronic inflammatory skin disease. Peripheral blood from psoriasis patients.These cells are derived from the mononuclear cell fraction of the blood, which mainly includes lymphocytes (T cells, B cells, NK cells) and monocytes. Morphologically, PBMCs appear as small and round cells. They play a central role in the pathogenesis of psoriasis. Upregulated inflammatory cytokines IL-17 and TNF-α from activated T cellsAbnormal activation of T cells secretes inflammatory factors such as IL-17 and TNF-α, which in turn leads to excessive proliferation of keratinocytes and chronic inflammation. Central role in psoriasis pathogenesis by driving keratinocyte proliferation and maintaining chronic skin inflammation.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human Psoriasis Peripheral Blood Mononuclear Cells can be used to study the pathogenesis of psoriasis, providing insights into the systemic immune dysregulation underlying psoriasis and its associated complications, such as psoriatic arthritis and cardiovascular disease. In addition, these cells also provide a platform for evaluating treatment responses (e.g., biologics targeting the IL-17/23 pathway) and identifying potential biomarkers of disease progression